OverT Bio Receives $120K G-Rex® Grant to Propel Solid Tumor Cell Therapy Advancements

On November 22, 2024 OverT Bio, an NYC-based cell therapy company, reported that it has been awarded a $120,000 G-Rex Grant from ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM (Press release, OverT Bio, NOV 22, 2024, View Source [SID1234648585]). This grant will support OverT Bio’s ongoing development efforts that will lead to next generation cell therapies for solid tumors, based on innovative data-driven discovery platforms OverTargetTM and OverTCRTM.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This grant, including its access to newly developed GMP closed system products and ScaleReady’s expertise, will help us accelerate the development of our products in a way that will ensure future scalability and cost-effectiveness of these potential medicines."

The G-Rex Grant is part of ScaleReady’s $20 million grant program aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. The G-Rex Grant Program offers recipients significant no-cost support allowing for expeditious optimization of cell manufacturing processes.

"We are pleased to receive ScaleReady’s support and their recognition of the potentially high impact our technology has to advance our shared mission of bringing new life-saving therapeutics to cancer patients," stated Mat Legut, PhD, CEO of OverT Bio. "This grant, including its access to newly developed GMP closed system products and ScaleReady’s expertise, will help us accelerate the development of our products in a way that will ensure future scalability and cost-effectiveness of these potential medicines."

"Our support of OverT Bio is yet another example of how our G-Rex Grant Program is being used to facilitate advancement of the field of cell and gene-modified cell therapy," said Josh Ludwig, Commercial Director of ScaleReady. "The G-Rex Grant Program augments ScaleReady’s primary purpose of providing every CGT company with the ability to save time and money while building a strong value proposition for continued investment on favorable terms."